<DOC>
	<DOC>NCT02262663</DOC>
	<brief_summary>This is a study in healthy women of reproductive age to investigate the pharmacodynamics (mainly ovarian activity), pharmacokinetics and safety of vilaprisan after daily oral administration of 4 different doses over 84 days, using a randomized, parallel-group, multicenter design.</brief_summary>
	<brief_title>Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan</brief_title>
	<detailed_description />
	<criteria>Body mass index (BMI): ≥ 18 and ≤ 32 kg/m² at the first screening visit Absence of clinically relevant abnormal findings in the pretreatment endometrial biopsy Pretreatment cycle assessed as ovulatory and not longer than 44 days Incompletely cured preexisting diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal Known or suspected liver disorders Amenorrhea for more than 3 months within the last 6 months before the first screening examination Clinically relevant findings (e.g. blood pressure, electrocardiogram [ECG], physical and gynecological examination, laboratory examination) Positive urine pregnancy test Regular use of medicines</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>